Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence

View Full Paper
Ask AI
Bookmark
Share

Authors

OSOndřej SoučekLVLenka Janska VojtkovaMBMarek Borský

Discussion

Loading...

Member takes

Overview

Multicenter analysis reveals distinct kinetics, persistence, and associated toxicities in CAR-T products, highlighting clinical implications.

Key Points

  • Distinct kinetics and persistence of chimeric antigen receptor T cells were observed across CD19 and BCMA therapies in hematologic malignancies.
  • Cilta-cel exhibited significantly higher peak counts compared to axi-cel and brexu-cel, indicating varying expansion patterns among CAR-T products.
  • Observational analysis of CD4/CD8 kinetics showed unique patterns of toxicity associated with chimeric antigen receptor T cell expansion.
  • Increased toxicity was linked to improved clinical efficacy, suggesting a complex relationship between CAR-T kinetics and treatment outcomes.

Cite This Study

Souček et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d3https://doi.org/10.1182/blood-2025-5721
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.2026
  4. 4Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025
  5. 5Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma2025